INTRODUCTION
============

According to the International Society for the Study of Vascular Anomalies (ISSVA) classification, vascular anomalies are classified into vascular tumors with proliferative changes in endothelial cells and vascular malformation characterized by abnormal dilation of blood vessels without proliferative change. The former includes infantile hemangioma, tufted angioma and Kaposiform hemangioendothelioma (KHE).

The disease concept of KHE was first proposed by Zukerberg in 1993.^[@r1]^ The intermediate malignant tumor is a rare, locally aggressive, vascular tumor that usually occurs during childhood. KHE may be associated with Kasabach-Merritt syndrome (KMS), a severe condition characterized by profound thrombocytopenia and hemorrhage. Because its mortality has been reported as 24%, it is necessary to clarify this tumor\'s detailed pathogenesis to develop early diagnostic methods and new therapeutic strategies. ^[@r2]^

The tumor\'s etiology remains unknown. Diagnosing KHE depends on histopathologic examination. The tumor is filled with slit-like vascular spaces and intracellular lumina, sometimes infiltrating muscles and subcutaneous fat tissue. The neoplastic tumor cells at the periphery of the tumor were positive for CD31, CD34 and lymphatic markers (D2-40, Prox1 or LYVE-1). Nevertheless, these cells were negative for GLUT-1 (infantile hemangioma marker) and HHV-8 (Kaposi\'s sarcoma marker).

No treatment guidelines exist for KHE. Previous reports have indicated that complete surgical excision is the most reliable treatment.^[@r3]^ When surgical excision is impossible, combined therapy, including high-dose steroids, cytotoxic agent (vincristine or interferon-α) and cyclophosphamide, is required. Furthermore, a small number of studies have reported the effects of sirolimus, β-blocker, radiotherapy and embolization.^[@r4],[@r5]^ However, the tumor is basically resistant to such treatments and complete remission is usually difficult to achieve.

Recently, advances in sequencing methods have enabled the identification of driver genes in many cancers. For example, mutations in BRAF are found in malignant melanoma, and BRAF inhibitors have already been utilized as novel treatments. Nonetheless, no studies exist on the causative genes in KHE. In this study, we performed exome sequencing of KHE and found putative candidates for the responsible mutations.

METHOD
======

Case
----

A 2-year-old Japanese boy visited our hospital to treat eruptions. His parents had noticed erythemas on his lower abdominal area at birth. His eruption was monitored at another hospital but the lesion gradually became larger, violaceous and painful.

On physical examination at the first visit, multiple, indurated nodules and erythemas merged to become geographical ([Figure 1](#f1){ref-type="fig"}). His general condition was good and there was no record of any similar condition in his family history. Laboratory data including platelet count, prothrombin time, activated partial thromboplastin time and international normalized ratio were within the normal range. T2-weighted magnetic resonance imaging (MRI) revealed multiple subcutaneous nodules, enhanced by intravenous contrast agent ([Figure 2](#f2){ref-type="fig"}). No apparent invasion into the muscle or fascia was noted. Hematoxylin and Eosin (H&E)-stained sections of skin biopsy specimen from the lesion showed multiple nests of tumor cells in the dermis and fat tissue without epidermal change ([Figure 3](#f3){ref-type="fig"}). The tumor cells were spindle-shaped or round, containing interspersed capillaries with slit-like lumens and red blood cells. Slight nuclear variation was observed, but no significant nuclear mitosis, atypia or necrosis. Histopathologically, these tumor cells were positive for CD31 and CD34, but negative for GLUT-1. In addition, D2-40 was positive in the peripheral area of tumor nests and negative in the surrounding dilated vessels ([Figure 3](#f3){ref-type="fig"}).

Figure 1Violaceous and indurated multiple lesions in the abdomen

Figure 2MRI of the abdomen. Arrows indicate multiple, subcutaneous nodules enhanced by intravenous contrast agent

Figure 3**A.** Hematoxylin-eosin staining of biopsy specimen from cutaneous lesion. Multiple nests of tumor cells in the dermis and fat tissue. Magnification x40; **B.** Hematoxylin-eosin staining of biopsy specimen from cutaneous lesion. The tumor cells were spindle-shaped or round, containing interspersed capillaries with slit-like lumens. There was slight nuclear variation. Magnification x400; **C.** D2-40 staining showing positiveness in peripheral area of tumor nests, but not in the surrounding dilated vessels. Magnification x200

Based on the above findings, a diagnosis of KHE was made. Since the tumor was limited to the lower abdomen without muscle infiltration or distant metastasis, and because the patient was not accompanied with KMS, the decision was taken to treat the tumor by serial excision. Three times resection removes almost all the lesions and the pain disappears.

DNA purification
----------------

The genomic DNA for exome sequencing was obtained from the tumor tissue and matched normal tissue from the same individual, using the DNA mini kit (Qiagen, Valencia, CA). Institutional review board approval and informed consent were obtained, conforming to the Declaration of Helsinki.

Library preparation and sequencing
----------------------------------

Exome sequencing was performed in accordance with the protocol provided by InfoBio (Tokyo, Japan). DNA was treated with the TruSeq DNA Sample Prep kit and TruSeq Exome Enrichment kit (Illumina, San Diego, CA) to provide libraries, which were sequenced on the HiSeq2000 sequencer platform (Illumina) in a paired-end 100bp configuration. Image analysis and base calling were performed using the Illumina pipeline.

The clean and trimmed reads were aligned to the reference human genome (UCSC hg19) using Burrows-Wheeler Aligner (BWA) on default settings. The bioinformatic analysis for detecting single nucleotide variants (SNVs) and inserts/deletions was performed using the Samtools (v1.0) software program and annotated according to dbSNP.

RESULT
======

High-quality DNAs were isolated from excised tumor tissue and matched normal tissue was derived from the same individual; these were then analyzed using paired-end exome sequences on the Illumina HiSeq2000 platform.

When compared with the reference human genome (UCSC hg19), there were 80,062 nucleotide changes in the normal tissue, and 73,878 changes in the tumor tissue. Among them, 68,342 changes were common to both tissues. We tried to extract SNVs and inserts/deletions likely to be associated with the pathogenesis.

First, we focused on oncogenes. Among APC, BCL2, TP16, FOS, MYC, TP53, RAS and VHL, as shown in [table 1](#t1){ref-type="table"}, the missense SNVs with a T-to-A transition or a G-to-C transition were observed in the TP53 or APC genes of tumor tissue, respectively. However, these SNVs were not tumor-specific changes because they were also noted in the matched normal tissue. The APC sequence change rs459552 is present in 86% of the population, according to allele frequency from the 1,000 genomes project of October 2011, indicating that SNV represents a common variant. However, although TP53 T-to-A transition rs1042522 is reportedly found in 60%, it was reported in several malignant tumors, and germline mutations in rs1042522 are thought to be associated with Li--Fraumeni syndrome, which is characterized by a hereditary predisposition to several cancers.^[@r6],[@r7]^ Accordingly, this germline SNV may be the pathologic change.

###### 

Changes observed in oncogenes

  Gene   Chr   Chr_start   Region   Homo/Hetero   Ref   Alt   Amino acid change   Genetic status
  ------ ----- ----------- -------- ------------- ----- ----- ------------------- ----------------
  APC    5     112176756   exonic   Homo          T     A     V→D                 germline
  TP53   17    25358943    exonic   Homo          G     C     R→P                 germline

Chr; chromosome, Chr_start: chromosome start site, Homo/Hetero; heterozygosity status, Ref; reference allele, Alt; alternative allele.

Subsequently, the team tried to uncover tumor-specific somatic mutations. Among the nonsynonymous SNVs, stop/gain SNVs or insertions/deletions observed only in tumor tissue and not in normal tissue, 81 candidate genes were selected by the following criteria: 1) frequency of under 1%; and 2) alternative depth/reference depth ratio of above 0.5 in heterozygous changes ([Tables 2](#t2){ref-type="table"}-[4](#t4){ref-type="table"}). Missense changes were seen in 68 genes ([Table 2](#t2){ref-type="table"}). In addition, PTRF, OLFML2A, WDR81, or DIDO1 were detected as stop/gain SNVs ([Table 3](#t3){ref-type="table"}). Eight out of the 9 insertions/deletions did not cause frameshift and only G insertion in the IL-32 gene resulted in frameshift ([Table 4](#t4){ref-type="table"}).

###### 

Missense somatic changes

  Gene       Chr     Chr_start   Ref   Alt   Homo/Hetero   Ref_depth   Alt_depth
  ---------- ------- ----------- ----- ----- ------------- ----------- -----------
  AQP11      chr11   77301121    G     A     Homo          0           2
  CHST6      chr16   75513276    G     T     Hetero        3           2
  DHPS       chr19   12792439    C     A     Hetero        3           2
  GAL3ST2    chr02   242742895   C     A     Hetero        3           2
  PTPN21     chr14   88945674    G     T     Hetero        3           2
  PYDC1      chr16   31228226    C     A     Hetero        3           2
  ZBTB4      chr17   7366209     A     G     Hetero        3           2
  SELRC1     chr01   53158524    A     C     Hetero        10          8
  FAM135A    chr06   71187020    A     C     Hetero        11          9
  CEMP1      chr16   2580996     T     G     Hetero        4           4
  GLB1L      chr02   220107628   C     A     Hetero        2           2
  NFIC       chr19   3435089     G     T     Hetero        2           2
  R3HDM4     chr19   899473      C     G     Hetero        2           2
  RASSF1     chr03   50375431    T     G     Hetero        5           7
  PLEKHH3    chr17   40824327    G     T     Hetero        1           2
  ZNF512B    chr20   62594752    C     A     Hetero        1           2
  GPRC5B     chr16   19883282    G     A     Hetero        1           3
  ITPRIPL2   chr16   19126384    C     A     Homo          0           2
  ITPRIPL2   chr16   19126388    C     A     Homo          0           2
  LRRC24     chr08   145749537   C     A     Homo          0           2
  MBD3L5     chr19   7032880     A     G     Homo          0           2
  PTPMT1     chr11   47587479    C     A     Homo          0           2
  TFR2       chr07   100228635   T     C     Homo          0           2
  TTLL4      chr02   219603798   A     C     Homo          0           3
  ZAR1L      chr13   32885737    G     T     Homo          0           2
  ABCB11     chr02   169828367   T     G     Hetero        15          8
  RETSAT     chr02   85571228    G     C     Hetero        13          7
  CLIP1      chr12   122812693   G     T     Hetero        7           4
  FAM75A6    chr09   43627675    C     A     Hetero        44          26
  DNAH12     chr03   57438710    C     A     Hetero        13          8
  CRLF1      chr19   18705064    C     T     Hetero        3           2
  GPIHBP1    chr08   144297240   C     A     Hetero        3           2
  GRID2IP    chr07   6542766     C     A     Hetero        3           2
  ITGB2      chr21   46309368    C     A     Hetero        3           2
  PABPC1     chr08   101719004   G     A     Hetero        35          24
  OR11H1     chr22   16449784    C     A     Hetero        31          23
  CATSPERG   chr19   38851455    A     C     Hetero        4           3
  CLEC18B    chr16   74451970    G     C     Hetero        4           3
  PABPC1     chr08   101719201   A     G     Hetero        25          20
  RASAL1     chr12   113544922   A     C     Hetero        5           4
  CDC27      chr17   45234417    A     G     Hetero        41          34
  SPATA20    chr17   48626182    A     C     Hetero        6           5
  MUC7       chr04   71347171    C     T     Hetero        20          17
  BCOR       chrX    39931672    C     A     Hetero        2           2
  C19orf57   chr19   14001212    C     A     Hetero        2           2
  CARD9      chr09   139264769   G     T     Hetero        2           2
  CRB1       chr01   197313422   G     A     Hetero        3           3
  DDX18      chr02   118572361   A     C     Hetero        3           3
  IL22RA1    chr01   24469556    G     T     Hetero        2           2
  MAD1L1     chr07   2108930     G     T     Hetero        2           2
  MRGPRE     chr11   3249491     A     C     Hetero        2           2
  OBSCN      chr01   228400288   G     T     Hetero        2           2
  SNED1      chr02   241974126   G     T     Hetero        2           2
  ARSH       chrX    2936675     T     G     Hetero        5           8
  CACNA1I    chr22   40045803    G     T     Hetero        1           2
  LRFN4      chr11   66627620    G     T     Hetero        1           2
  MRC2       chr17   60767030    C     A     Hetero        1           2
  SHROOM2    chrX    9862832     G     T     Hetero        1           2
  LAG3       chr12   6884651     A     C     Hetero        3           7
  OBSL1      chr02   220422281   C     T     Hetero        1           3
  TTN        chr02   179419226   A     C     Hetero        1           3
  USP49      chr06   41774685    C     G     Hetero        1           3
  GPRIN2     chr10   46999604    A     G     Hetero        2           12
  ADAMTS7    chr15   79058378    A     G     Homo          1           8
  FAM83E     chr19   49116421    G     T     Homo          0           2
  LILRB3     chr19   54725745    A     G     Homo          0           4
  NKX6-2     chr10   134598908   C     A     Homo          0           2
  PFKL       chr21   45744745    G     T     Homo          0           2

Chr; chromosome, Chr_start: chromosome start site, Ref; reference allele, Alt; alternative allele, Homo/Hetero; heterozygosity status, Ref_depth; read depth of reference allele, Alt_depth; read depth of alternative allele.

###### 

Nonsense somatic changes

  Gene      Chr     Chr_start   Ref   Alt   Homo/Hetero   Ref_depth   Alt_depth
  --------- ------- ----------- ----- ----- ------------- ----------- -----------
  PTRF      chr17   40557025    C     A     Hetero        3           2
  OLFML2A   chr09   127549304   C     A     Hetero        2           2
  DIDO1     chr20   61542820    C     A     Homo          0           2
  WDR81     chr17   1636925     G     T     Homo          0           2

Chr; chromosome, Chr_start: chromosome start site, Ref; reference allele, Alt; alternative allele, Homo/Hetero; heterozygosity status, Ref_depth; read depth of reference allele, Alt_depth; read depth of alternative allele.

###### 

Insertion/deletion somatic changes

  Gene      Chr     Chr_start   Ref               Alt   Homo/Hetero   Ref_depth   Alt_depth
  --------- ------- ----------- ----------------- ----- ------------- ----------- -----------
  IL32      chr16   3119303     \-                G     Hetero        25          15
  FAM48B1   chrX    24382426    GCT               \-    Homo          0           2
  ATXN1     chr06   16327915    ATG               \-    Hetero        1           3
  HAVCR1    chr05   156479571   CATTGGAACAGTCGT   \-    Homo          0           20
  PCDHB10   chr05   140574177   GGCCGA            \-    Homo          0           4
  POLI      chr18   51795967    CGA               \-    Homo          0           5
  CCDC66    chr03   56650056    \-                TCT   Homo          0           31
  FAM83G    chr17   18874687    \-                GGG   Homo          0           2
  NR1H2     chr19   50881831    \-                CAG   Homo          0           7

Chr; chromosome, Chr_start: chromosome start site, Ref; reference allele, Alt; alternative allele, Homo/Hetero; heterozygosity status, Ref_depth; read depth of reference allele, Alt_depth; read depth of alternative allele.

DISCUSSION
==========

KHE is a rare, vascular tumor experienced in childhood that invades skin and cutaneous tissues locally. The prognosis of KHE accompanied with KMS is rather poor. Specific driver mutations of the tumor remain unknown. This is the first study to investigate mutations using the exome sequence, and we described several putative causing mutations of KHE.

For instance, the putative germline mutation seen in both tumor tissue and matched normal tissue was TP53 rs1042522. Given that TP53-deficient mice developed several spontaneous tumors including angiosarcoma, another malignant vascular tumor, TP53 mutation may play a role in the tumorigenesis of vascular tumors.^[@r8]^ However, since this SNV is seen in about 60% of the population, there is a possibility that \"second-hit\" somatic mutation is also necessary for tumorigenesis. Another vascular anomaly, mucocutaneous venous malformation is caused by the combination of germline substitutions in the endothelial cell tyrosine kinase receptor TIE2 and the somatic \'second hit\' lesion-restricted mutation of TIE2.^[@r9]^ Similarly, we previously indicated germline heterozygous SNV in KDR and TEM8 as the risk mutations for infantile hemangioma.^[@r10]^ As infantile hemangioma typically appears on the head or face around the second week of life, the hypothesis proposed is that the clonal expansion of endothelial cells within the lesions may be a consequence of somatic events such as microvessel trauma during delivery.

We also identified 81 genes as candidates for somatic mutation. For example, ITGB2 has been strongly implicated in angiogenesis, suggesting the possible association with the pathogenesis of KHE. IL-32, which possesses heterozygous frameshift in KHE tissue, has also been known as a angiogenesis-related cytokine.^[@r11],[@r12]^ Furthermore, we found 4 nonsense mutations only in tumor tissue, including the DIDO1 gene, which is up-regulated by apoptotic signals and encodes a cytoplasmic protein that translocates to the nucleus upon apoptotic signal activation. DIDO1 is considered a tumor suppressor gene in myeloid cells, and thought to be significantly involved in the pathogenesis of myelodysplastic syndrome, a malignant blood disorder.^[@r13]^ Accordingly, the DIDO1 gene may also be involved in the tumorigenesis of KHE.

CONCLUSION
==========

These mutations have not been reported so far, which is consistent as driver mutations of the rare tumor. Potentially, multiple genetic abnormalities - rather than a single abnormality -- may be involved in KHE. For instance, germline TP53 SNV and the somatic DIDO1 gene change may cooperate to induce tumorigenesis.

As limitations to this study, \'germline\' mutation of TP53 may be due to the contamination of normal tissue and tumor tissue, because the parent DNA is not determined. In addition, the result of exome analysis was not confirmed by the sanger method. Since KHE is a rare tumor, the team was unable to collect other samples. This is a pilot study, and future analysis with more patients is needed to clarify: this tumor\'s detailed pathogenesis, the novel diagnostic methods by detecting specific mutations, and the new therapeutic strategies targeting the mutation.
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